Testing Intermittent Calorie Restriction in Adults With Mild to Moderate Crohn's Disease
Tests periodic calorie restriction in adults with mild to moderate Crohn's disease.
Key facts
- Who runs it
- Central Hospital, Nancy, France
- Where
- Vandœuvre-lès-Nancy, FranceSee the site
- Trial code
- Registry title
- Intermittent Caloric Restriction in Patients With Mild to Moderate Crohn's Disease
- Status
- Recruiting
- People taking part
- 174 people, planned
- Started
- 18 Apr 2023
- Expected to end
- 1 Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Intermittent caloric restriction
- Record updated
- 8 June 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild to moderate Crohn's disease who are on a stable treatment and can follow intermittent caloric restriction for 16 weeks.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Crohn's disease diagnosed at least 3 months ago, mild to moderate: fecal calprotectin ≥ 250 μg/g and a CDAI score between 150 to 300.
- Earlier treatment
- Medical treatment for Crohn's disease stable for at least 3 months.
- Biomarker or test result
- Fecal calprotectin ≥ 250 μg/g.
Main reasons for not taking part
- BMI below 18.5kg/m2
- Active ano-perineal lesions
- An ostomy
- Eating disorders (anorexia, bulimia)
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients between 18 to 65 years old
- Established diagnosis of Crohn's disease with a minimum disease duration of 3 months
- Patient with mild to moderate Crohn's disease defined by a fecal calprotectin ≥ 250 μg/g and a CDAI score between 150 to 300
- Medical treatment of Crohn's disease stable for at least 3 months
- Patient compliant with an intermittent caloric restriction during 16 weeks
- Person affiliated to or beneficiary of a social security plan
- Person informed about study organization and having signed the informed consent
Who cannot take part
- Patient with eating disorders (anorexia, bulimia)
- Person deprived of liberty for judicial or administrative decision, person under psychiatric care as referred in articles L. 3212-1 and L. 3213-1
- Patient with a BMI < 18.5kg/m2
- Patient having a weight loss of 5% the first month and 10% during the first 6 months
- Patient with active ano-perineal lesions
- Patient with an ostomy
- Person referred in articles L.1121-5, L. 1121-7 and L.1121-8 of the Public Health Code:; Pregnant, parturient or breastfeeding woman; Minor person (non-emancipated); Adult person under legal protection (any form of public guardianship); Adult person incapable of giving consent and not under legal protection
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in France
- CHRU of NANCYVandœuvre-lès-Nancy, FranceContact: CARON Bénédicte, MDTaking people
About the trial
What the trial wants to find out
Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal (GI) tract. CD is a common inflammatory bowel disease (IBD), frequent (150,000 patients in France and 1.5 million in Europe), disabling and incurable. The environmental factors, and in particular diet, play a major role in the pathogenesis of CD. The prevalence of CD is steadily increasing in highly industrialized countries, where the Western diet rich in saturated fats and refined sugars, is blamed for this to explain this true pandemic. On the other hand, enteral nutrition, exclusive or partial, is known to be effective in the initial treatment of CD, especially in pediatrics.
Read full original descriptionShow less
There are a number of evidence in favor of a nutritional management nutritional management of caloric restriction during inflammatory diseases such as psoriasis and rheumatoid arthritis,whose physiopathology is similar to that of IBD.
To date, and despite patient concern, there is no consensus nutritional in the management of CD to influence the natural course of the disease.
The investigators have decided to initiate a clinical study to evaluate for the first time the efficacy, acceptability and safety of intermittent caloric restriction in patients with CD.
The 2 groups in the trial
- Intermittent caloric restrictionTreatment being tested
Intermittent caloric restriction during 16 weeks.
- Routine practiceNo study treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Intermittent Caloric Restriction in Patients With Mild to Moderate Crohn's Disease: A Randomized, Open-label, Controlled Trial
- Plain-language title
- Testing Intermittent Calorie Restriction in Adults With Mild to Moderate Crohn's DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT05683730, who can take part
- Record updated
- 8 June 2023